Anthropic Acquires Solo Biotech Founder, Expands Drug Discovery
Anthropic acquired Mithril Medicine — a one-person biotech company treating rare childhood muscular dystrophy — after the founder used Claude to coordinate 11 external labs. The solo founder is revealed to be anonymous CT account @Prof_Oak_ after 6 years of anonymity.
What we know
The story broke through multiple feeds: An account on X reported that Anthropic acquired Mithril Medicine in July 2026 — a solo-founder company developing treatments for two rare forms of muscular dystrophy, with the founder using Claude to organize contracts, logistics, and experiments across 11 external labs. Another account on X RT'd the reveal that the solo founder is the long-anonymous CT account another account on X, unmasked after 6 years. @cz_binance reacted with characteristic humor, noting the 10-year FDA approval process will be the real bottleneck even with AI acceleration. Cointelegraph reported Anthropic is now working with six organizations to accelerate drug development using Claude.
How the story developed
Anthropic acquired Mithril Medicine — a one-person biotech company treating rare childhood muscular dystrophy — after the founder used Claude to coordinate 11 external labs. The solo founder is revealed to be anonymous CT account @Prof_Oak_ after 6 years of anonymity.
Anthropic acquired rare disease biotech Mithril Medicine and is linked to a $63B financing deal with Broadcom, with Avago shares up 4% on the news. Anthropic also faces a piracy lawsuit at Stanford with a judge named 'Alsup.'
Anthropic's S-1 filing drew skepticism over withheld Q3 growth data and questions about why a cash-flow-positive company is IPOing. A $40B AI debt deal brokered by Broadcom's CEO for Anthropic's TPU purchases nearly collapsed before last-minute bank commitments.
Sources
“That's very cool. The limiting factor will become the 10 year trial/approval process. Maybe they will also use AI to review?”
View post →By the Global Eye 24 desk, with AI assistance. Updated as the story develops. Spot an error? Write to corrections@globaleye24.com.